Elanco Receives USDA Approval for Befrena, Anti-IL31 Monoclonal Antibody for Canine Dermatitis
核心洞察
Elanco Animal Health (搜索) received USDA approval for Befrena (搜索) (tirnovetmab (搜索)), a new anti-IL31 (搜索) monoclonal antibody injection targeting canine allergic and atopic dermatitis.
The treatment offers 6 to 8 weeks of relief with a longer dosing interval compared to the current market competitor lokivetmab (搜索), which requires dosing every 4 to 8 weeks.
This marks Elanco's second dermatology product approval in less than 18 months in the estimated $1.3 billion U.S. canine dermatology market.
Elanco Animal Health (搜索) Incorporated announced the U.S. Department of Agriculture (USDA) approval of Befrena (搜索)™ (tirnovetmab (搜索)), a new anti-IL31 (搜索) monoclonal antibody injection targeting canine allergic and atopic dermatitis. The approval represents Elanco's latest entry into the rapidly growing canine dermatology space and marks the company's second dermatology product approval in less than 18 months.
Treatment Profile and Competitive Positioning
Befrena (搜索) has demonstrated effectiveness for treating dogs of any age against canine atopic dermatitis (搜索) and allergic dermatitis, providing 6 to 8 weeks of treatment relief as needed. The dosing interval of 6 to 8 weeks post-treatment offers a potential advantage over the current market competitor lokivetmab (搜索), which requires administration every 4 to 8 weeks.
The approval reinforces Elanco's position in the estimated $1.3 billion U.S. canine dermatology market and bolsters the company's leadership in canine dermatology and monoclonal antibodies. Elanco expects to launch Befrena (搜索) in the first half of 2026.
Expanding Dermatology Portfolio
Befrena (搜索) joins Zenrelia (搜索)™ (ilunocitinib (搜索) tablets), Elanco's once-daily oral JAK inhibitor for controlling itching and inflammation associated with skin allergies in dogs at least 12 months of age. In September, Elanco announced improvements to the U.S. Zenrelia label, with the Food and Drug Administration concluding "the totality of evidence supports removal of the risk of fatal vaccine-induced disease from modified live virus vaccines from the labeling."
The label Boxed Warning continues to advise discontinuation of Zenrelia (搜索) for at least 28 days to 3 months prior to vaccination and withholding Zenrelia for at least 28 days after vaccination.
Market Need and Clinical Impact
Canine allergic and atopic dermatitis represents a widespread concern among veterinarians, with data revealing that nearly 98% of veterinarians routinely treat dogs for atopic dermatitis and itchy dogs make up nearly 20% of their patient population.
"The animal health sector is increasingly focused on antibody-based therapies, and today's approval is an important step forward in delivering high-impact innovation that enhances the quality of life for pets," said Dr. Ellen de Brabander, Executive Vice President of Research & Development at Elanco. "We are pleased to offer veterinarians and pet owners Befrena (搜索), which delivers long lasting relief to treat dogs with allergic itch."
Understanding the Burden of Canine Dermatitis
Elanco's America's Itchy Dogs Report, launched earlier this year, highlighted the significant impact of itch on dogs, their owners, and veterinarians. The first-of-its-kind report revealed that 9 in 10 dogs in the U.S. are "itchy dogs" according to their pet owners, having experienced symptoms of itchiness at some point in the year.
The report found that pet owners typically try many at-home solutions before seeking veterinary care, spending an average of $400 on over-the-counter remedies and waiting six weeks before taking their pet to the veterinarian. Veterinarians report that itchy dog owners wait too long before bringing their dogs for treatment, resulting in raw and infected skin and frustrated pet owners seeking quick relief.
Research indicates that nearly 70% of veterinarians would be willing to stock another dermatology product to help more dogs find itch relief.
Veterinary Perspective
"Veterinarians need more options for itch relief so they can offer targeted therapy that focuses on mode of action to meet the unique needs of the individual patient to deliver fast, effective and valuable itch relief," said Dr. Griffin, veterinary dermatologist. "USDA approval of Befrena (搜索) brings veterinarians a step closer to having another beneficial and safe treatment option. I'm excited to collaborate with Elanco and plan to offer this product in my practice when it becomes available."